Inspire Medical Systems, Inc. (INSP) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. At $42.70, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak).
Inspire Medical Systems is a medical technology company that makes the Inspire system, the only FDA-approved closed-loop neurostimulation therapy for moderate-to-severe obstructive sleep apnea, treating over 125,000 patients. Revenue is generated by selling the implantable... Read more
Sell if holding. At $42.70, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak). Chart setup: Death cross but MACD improving, RSI 44. Score 5.1/10, high confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Inspire Medical Systems, Inc.
Latest news
- NEWS Inspire Medical Systems Inc (INSP) Stock Up 4.2% and Still Under - GuruFocus — GuruFocus positive
- NEWS Analysts estimate Inspire Medical Systems (INSP) to report a decline in earnings: What to look out for - MSN — MSN neutral
- NEWS Inspire Medical Systems (NYSE:INSP) Shares Down 8.3% - Time to Sell? - MarketBeat — MarketBeat negative
- NEWS Inspire Medical Systems (INSP) Q1 earnings and revenues top estimates - MSN — MSN positive
- NEWS Inspire Medical Systems Earnings Preview: Revenue Expected Flat - IndexBox — IndexBox negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductInspire system10-K Item 1A: 'our dependency on our Inspire system for revenues'
Material Events(8-K, last 90d)
- 2026-05-05Item 5.02LOWStockholders approved the 2026 Omnibus Incentive Plan at the May 7, 2026 Annual Meeting, authorizing 18,793,516 shares. Compensatory arrangement for executives; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $42.70, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak). Chart setup: Death cross but MACD improving, RSI 44. Prior stop was $39.71. Score 5.1/10, high confidence.
Take-profit target: $45.39 (+6.3% upside). Prior stop was $39.71. Stop-loss: $39.71.
Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak); Thin upside margin: 6.3%.
Inspire Medical Systems, Inc. trades at a P/E of 9.7 (forward 32.7). TrendMatrix value score: 5.7/10. Verdict: Sell.
24 analysts cover INSP with a consensus score of 3.4/5. Average price target: $52.
What does Inspire Medical Systems, Inc. do?Inspire Medical Systems is a medical technology company that makes the Inspire system, the only FDA-approved...
Inspire Medical Systems is a medical technology company that makes the Inspire system, the only FDA-approved closed-loop neurostimulation therapy for moderate-to-severe obstructive sleep apnea, treating over 125,000 patients. Revenue is generated by selling the implantable system to hospitals and ASCs in the US and select European markets through a direct sales force; Japan and Singapore use distributors. As of December 31, 2025, the company operated 295 US and 21 international sales territories.